Suven Life Sciences Ltd
SUVEN
Company Profile
Business description
Suven Life Sciences Ltd is an India-based biopharmaceutical company. The company is focused on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. The company's only segment is providing Research and Development services. The company's geographical segment includes India; the USA; Europe and Others. The company generates maximum revenue from the USA. The company earns revenue from the sale of New Chemical Entity (NCE) based Intermediates for CNS disorders.
Contact
Avenue 7, Road No. 5, Banjara Hills
Number 8-2-334, 6th Floor, SDE Serene Chambers
HyderabadTG500 034
INDT: +91 4023541142
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2027
Employees
187
Stocks News & Analysis
stocks
Older cohorts the budget losers, not necessarily the ASX listed insurers
Proposed legislation removes health insurance rebates.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,829.50 | 17.30 | 0.20% |
| CAC 40 | 8,038.44 | 50.95 | 0.64% |
| DAX 40 | 24,588.59 | 280.67 | 1.15% |
| Dow JONES (US) | 49,686.12 | 159.95 | 0.32% |
| FTSE 100 | 10,379.39 | 55.64 | 0.54% |
| HKSE | 25,797.85 | 122.67 | 0.48% |
| NASDAQ | 26,090.73 | 134.41 | -0.51% |
| Nikkei 225 | 60,550.59 | 265.36 | -0.44% |
| NZX 50 Index | 12,974.32 | 211.40 | 1.66% |
| S&P 500 | 7,403.05 | 5.45 | -0.07% |
| S&P/ASX 200 | 8,604.70 | 23.10 | 0.27% |
| SSE Composite Index | 4,169.54 | 38.01 | 0.92% |